Case Report: Home-based Management of Severe COVID-19 with Low-dose Tofacitinib.
Ontology highlight
ABSTRACT: Human lives and nations' economies have been adversely affected worldwide by the COVID-19 pandemic. The hyperinflammatory state associated with the disease may be related to mortality. Systemic glucocorticoid is the first-line therapy for cytokine storm. Various immunomodulatory drugs such as tocilizumab and baricitinib have been used in those not responding to glucocorticoid monotherapy. Amid the peak crisis of COVID-19 in India, there was an extreme paucity of medications, oxygen, and hospital beds. We describe three patients with COVID-19 who received low-dose tofacitinib (an oral Janus kinase inhibitor) in addition to moderate-dose glucocorticoid. These patients were treated at their homes, as the hospitals were short of beds. Rapid reduction in hypoxemia along with gradual resolution
SUBMITTER: Sharma A
PROVIDER: S-EPMC8641367 | biostudies-literature | 2021 Oct
REPOSITORIES: biostudies-literature
ACCESS DATA